Article info
PDFSpecial communication
Altria-Juul Labs deal: why did it occur and what does it mean for the US nicotine delivery product market
- Correspondence to Dr David T Levy, Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washinton, DC 20007, USA; dl777{at}georgetown.edu
Citation
Altria-Juul Labs deal: why did it occur and what does it mean for the US nicotine delivery product market
Publication history
- Received March 29, 2019
- Revised July 12, 2019
- Accepted July 17, 2019
- First published September 4, 2019.
Online issue publication
December 09, 2020
Article Versions
- Previous version (9 December 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.